Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 1
2010 4
2011 5
2012 1
2013 8
2014 8
2015 6
2016 5
2017 5
2018 6
2019 6
2020 6
2021 5
2022 8
Text availability
Article attribute
Article type
Publication date

Search Results

67 results
Results by year
Filters applied: . Clear all
Page 1
Reversing dopaminergic sensitization.
Castrioto A, Carnicella S, Fraix V, Chabardes S, Moro E, Krack P. Castrioto A, et al. Mov Disord. 2017 Dec;32(12):1679-1683. doi: 10.1002/mds.27213. Epub 2017 Nov 18. Mov Disord. 2017. PMID: 29150871 Review. No abstract available.
Predictors of Long-Term Outcome of Subthalamic Stimulation in Parkinson Disease.
Cavallieri F, Fraix V, Bove F, Mulas D, Tondelli M, Castrioto A, Krack P, Meoni S, Schmitt E, Lhommée E, Bichon A, Pélissier P, Chevrier E, Kistner A, Seigneuret E, Chabardès S, Moro E. Cavallieri F, et al. Among authors: castrioto a. Ann Neurol. 2021 Mar;89(3):587-597. doi: 10.1002/ana.25994. Epub 2021 Jan 9. Ann Neurol. 2021. PMID: 33349939
Hyperdopaminergic behavioral spectrum in Parkinson's disease: A review.
Béreau M, Fleury V, Bouthour W, Castrioto A, Lhommée E, Krack P. Béreau M, et al. Among authors: castrioto a. Rev Neurol (Paris). 2018 Nov;174(9):653-663. doi: 10.1016/j.neurol.2018.07.005. Epub 2018 Sep 14. Rev Neurol (Paris). 2018. PMID: 30224159 Review.
Long-term Outcomes (15 Years) After Subthalamic Nucleus Deep Brain Stimulation in Patients With Parkinson Disease.
Bove F, Mulas D, Cavallieri F, Castrioto A, Chabardès S, Meoni S, Schmitt E, Bichon A, Di Stasio E, Kistner A, Pélissier P, Chevrier E, Seigneuret E, Krack P, Fraix V, Moro E. Bove F, et al. Among authors: castrioto a. Neurology. 2021 Jun 2:10.1212/WNL.0000000000012246. doi: 10.1212/WNL.0000000000012246. Online ahead of print. Neurology. 2021. PMID: 34078713
Emotional manifestations of PD: Neurobiological basis.
Castrioto A, Thobois S, Carnicella S, Maillet A, Krack P. Castrioto A, et al. Mov Disord. 2016 Aug;31(8):1103-13. doi: 10.1002/mds.26587. Epub 2016 Apr 4. Mov Disord. 2016. PMID: 27041545 Review.
Cerebrospinal fluid biomarkers in Parkinson disease.
Parnetti L, Castrioto A, Chiasserini D, Persichetti E, Tambasco N, El-Agnaf O, Calabresi P. Parnetti L, et al. Among authors: castrioto a. Nat Rev Neurol. 2013 Mar;9(3):131-40. doi: 10.1038/nrneurol.2013.10. Epub 2013 Feb 19. Nat Rev Neurol. 2013. PMID: 23419373 Review.
Serotonergic and Dopaminergic Lesions Underlying Parkinsonian Neuropsychiatric Signs.
Maillet A, Météreau E, Tremblay L, Favre E, Klinger H, Lhommée E, Le Bars D, Castrioto A, Prange S, Sgambato V, Broussolle E, Krack P, Thobois S. Maillet A, et al. Among authors: castrioto a. Mov Disord. 2021 Dec;36(12):2888-2900. doi: 10.1002/mds.28722. Epub 2021 Sep 8. Mov Disord. 2021. PMID: 34494685
The pathogenesis of Pisa syndrome in Parkinson's disease.
Castrioto A, Piscicelli C, Pérennou D, Krack P, Debû B. Castrioto A, et al. Mov Disord. 2014 Aug;29(9):1100-7. doi: 10.1002/mds.25925. Epub 2014 Jun 7. Mov Disord. 2014. PMID: 24909134 Review.
67 results